accountZURICH (Reuters) - Italian biotech Bioxell SpA said its Elocalcitol drug to treat overactive bladder (OAB) failed to reach its main target in a mid-stage clinical trial, and that it would cut costs, sending its stock to an all-time low.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Shares tumble as Bioxell lead drug fails in trial
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account